2023 Spotify Wrapped unveils the top artists, songs, albums, and podcasts that defined how we listened this year, and the new personalized Wrapped user experience 

HO CHI MINH CITY, Vietnam, Nov. 30, 2023 /PRNewswire/ — Spotify today unveils its 2023 Wrapped campaign – announcing the top artists, albums, songs, and podcasts that defined how over 574 million people around the world listened this year. Users can also discover their personalized Wrapped user experience when they open Spotify, packed with brand new interactive features to celebrate their year on Spotify.   

Spotify unveils 2023 Wrapped user experience

2023 was defined by the epic return of major female artists, sonic diversity across the charts, and a global music culture that saw the rise of powerful genres. Spotify’s top lists reflect these trends and the overall expansion of music and podcasts as Spotify continues to grow its user base.

Globally, Taylor Swift takes the reign as Spotify’s top artist this year – followed by Bad Bunny (#2), The Weeknd (#3), Drake (#4), and Peso Pluma (#5).

Closer to home, here’s how Vietnam listened in 2023: 

Jung Kook comes in first on the list of Vietnam’s Top Artists of the Year while BTS ranks at #3, once again proving the nation’s love for the K-Pop genre. The boys of BTS also continue to dominate the list of Vietnam’s Top Songs of the Year. In addition to "Seven (feat. Latto)" by Jung Kook topping the list, "Like Crazy" by Jimin comes in at #2, and "Slow Dancing" by V ranks at #5. Charlie Puth‘s "Left and Right", which featured Jung Kook, also ranks on the list at #3.

This year, we also continue to witness strong support for homegrown talent as three Vietnamese musicians rank amongst the list of Vietnam’s top five most-streamed artists. RPT MCK comes in strong at #2, while GREY D ranks #4. Entering the list this year is tlinh, who was crowned 2022’s Top EQUAL Vietnam Artist of the Year after ranking first on the roster of artists that were featured on Spotify’s gender equity program dedicated to amplifying women creators and their music. As she continues to capture the hearts of listeners in Vietnam in 2023, tlinh rounds off Vietnam’s list of Top Artists of the Year at #5. Her hit song, "nếu lúc đó" also ranks as the fourth most-streamed song in Vietnam in 2023.

This year, the title of Top EQUAL Vietnam Artist goes to Suni Hạ Linh. 

Last but not least, since being featured on Spotify’s RADAR program this year, which is dedicated to showcasing emerging and talented artists around the world, new kid on the block kidsai is named the Top RADAR Vietnam Artist of the Year.

HOW THE WORLD LISTENED TO K-POP

This year, Spotify is also spotlighting K-Pop: the genre that has scaled the globe and proven that music, from anywhere in the world can transcend language and cultural boundaries. In celebration of the continued growth and export of the genre, 2023 Wrapped unveils the Global Top K-Pop Artists and Songs of the Year.

On top of the list of Global Top K-Pop Artists of the Year is BTS who maintained their stronghold from 2022. Next on the ranks are BLACKPINK at #2 and Jung Kook of BTS at #3. Proving they are forces to be reckoned with, 4th-gen sensations NewJeans and Stray Kids round off the top five, coming in at #4 and #5 respectively.

The BTS members and NewJeans continue to dominate on the global top five list of most streamed K-Pop songs this year. "Seven (feat. Latto)" by Jung Kook emerges at #1, while "Like Crazy" by bandmate Jimin comes in at #3. In a testament to their remarkable rookie year, NewJeans’ "OMG" and "Ditto" rank at #4 and #5 on the list respectively. Completing the roster at #2 is the viral hit "Cupid – Twin Ver." by FIFTY FIFTY.

YOUR WRAPPED PERSONALIZED USER EXPERIENCE

Eligible users can now access their personalized 2023 Wrapped experience exclusively in the Spotify mobile app (iOS and Android), and also this year, via web view on mobile or Desktop by heading to Spotify.com/Wrapped. Please make sure your Spotify app is updated to the latest version to access.

New interactive features on 2023 Spotify Wrapped

Here’s what to look out for when you open Spotify. Your Wrapped results can reveal what you were really feeling in 2023.

●  New data stories bringing you to the heart of their listening: In addition to your top artists, genres, songs, podcasts and minutes listened, we’re adding a few new features to look out for.

○  Me in 2023 celebrates a streaming habit that defined your listening this year. The experience will reveal one of 12 listening characters that best describes the way you listened on Spotify this year – examples include the Shapeshifter (you’re quick to move from one artist to the next), the Luminary (you play light, upbeat music more than others), or the Alchemist (you create your own playlists more than others do).

○  Sound Town matches you to a city based on your listening and shared artist affinity. Listening habits are shared in surprising ways across communities around the world, and 2023 Wrapped celebrates that.

●  Wrapped fan-favorites appear in a refreshed way users haven’t seen before:

○  Top 5 Genres story shows you how your top five music genres stacked up with a new sandwich-inspired design.

○  Top 5 Artists lets you see the month your listening peaked for each artist – painting a fuller picture of your entire year and all the moments that made it.

○  You will also get to hear from one of your top artists directly within your personalized Wrapped via Your Artist Messages. You can then visit the Wrapped feed for video messages from thousands of artists including Taylor Swift, RPT MCK, NewJeans, SZA, Jung Kook and more.

●  Wrapped Feed: Right on your Spotify Home screen, the Wrapped feed is the one-stop shop for all things Wrapped, including the best of editorial playlists, merch from your top artists, concerts near you, and more.

Bringing Blend to the Wrapped experience: This year, you can invite your friends to create a Blend and tap the ‘2023 Wrapped Top Songs’ filter to combine all of your top songs from this year into one shared playlist.

–  END –

Note to Editors: 

Please find the full top lists of artists, songs, playlists and podcasts in Vietnam, globally, and in K-Pop HERE.  For more information, visit For The Record. Hi-res images to include in your story are HERE.

ABOUT SPOTIFY

Spotify transformed music listening forever when we launched in 2008. Our mission is to unlock the potential of human creativity by giving a million creative artists the opportunity to live off their art and billions of fans the opportunity to enjoy and be inspired by these creators. Everything we do is driven by our love for music.

Discover, manage, and share over 100 million tracks, including 5 million podcast titles, and 350,000 audiobooks, for free, or upgrade to Spotify Premium to access exclusive features including improved sound quality and an on-demand, offline, and ad-free listening experience.

Today, we are the world’s most popular audio streaming subscription service with a community of more than 574 million users, including 226 million Spotify Premium subscribers, across more than 180 markets. We are also the largest driver of revenue to the music business today.

For more information, images, or to contact the press team, please head over to our press page at https://newsroom.spotify.com/.

Source : 2023 Spotify Wrapped: This Year, Music by Homegrown and K-Pop Artists Continue to Top Streams in Vietnam

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

2023 Spotify Wrapped unveils the top artists, songs, albums, and podcasts that defined how we listened this year, and the new personalized Wrapped user experience 

HONG KONG, Nov. 30, 2023 /PRNewswire/ — Spotify today unveils its 2023 Wrapped campaign – announcing the top artists, albums, songs, and podcasts that defined how over 574 million people around the world listened this year. Users can also discover their personalized Wrapped user experience when they open Spotify, packed with brand new interactive features to celebrate their year on Spotify.   

Spotify unveils 2023 Wrapped user experience

2023 was defined by sonic diversity across the charts and a global music culture that saw the rise of powerful genres. Our top lists reflect these trends and the overall expansion of music and podcasts as Spotify continues to grow its user base.

Globally, Taylor Swift takes the reigns as Spotify’s top artist this year – followed by Bad Bunny (#2), The Weeknd (#3), Drake (#4), and Peso Pluma (#5).

As Spotify celebrates its 10th year in Hong Kong, the 2023 Wrapped results demonstrate the listeners’ overwhelming love for homegrown music.

For yet another year, emerging on top as Hong Kong’s Top Artist of 2023 is Keung To, whose hits swept all the top 5 spots on the list of Hong Kong’s most-streamed songs. After "風雨不改 (電影《阿媽有咗第二個》主題曲)" at #1, "Dummy" and "追" follow at #2 and #3 respectively. "Dear My Friend" makes its return from last year’s list, ranking at #4 this year. Rounding off Hong Kong’s Top Songs of the Year is "濤" at #5.

Also on this year’s list of Hong Kong’s Top Artists are Canto-pop sensations Anson Lo 盧瀚霆 (#2), 陳卓賢 Ian (#3) and MC 張天賦 (#4). The undisputed King of Mandopop, Jay Chou, rounds off the list at #5. Special mention also goes to Canto-pop legend Eason Chan, who ranked fifth after MC 張天賦 on Hong Kong’s list of most-streamed local artists.

The list of Hong Kong’s most-streamed albums gives a peek into what else listeners were loving this year, which reflects an appreciation of music from the East and West. Following "This is MC" by MC 張天賦 at #1, "BORN PINK" by K-Pop supergroup BLACKPINK comes in at #2. Another K-Pop album on the top 5 list is "UNFORGIVEN" by LE SSERAFIM at #4. Completing the list are "Midnights" by Taylor Swift in #3 and Japanese star YOASOBI‘s "THE BOOK" in #5.

HOW THE WORLD LISTENED TO K-POP

This year, Spotify is also spotlighting K-Pop: the genre that has scaled the globe and proven that music, from anywhere in the world can transcend language and cultural boundaries. In celebration of the continued growth and export of the genre, 2023 Wrapped unveils the Global Top K-Pop Artists and Songs of the Year.

On top of the list of Global Top K-Pop Artists of the Year is BTS who maintained their stronghold from 2022. Next on the ranks are BLACKPINK at #2 and Jung Kook of BTS at #3. Proving they are forces to be reckoned with, 4th-gen sensations NewJeans and Stray Kids round off the top 5, coming in at #4 and #5 respectively.

The BTS members and NewJeans continue to dominate on the global top five list of most streamed K-Pop songs this year. "Seven (feat. Latto)" by Jung Kook emerges at #1, while "Like Crazy" by bandmate Jimin comes in at #3. In a testament to their remarkable rookie year, NewJeans’ "OMG" and "Ditto" rank at #4 and #5 on the list respectively. Completing the roster at #2 is the viral hit "Cupid – Twin Ver." by FIFTY FIFTY.

YOUR WRAPPED PERSONALIZED USER EXPERIENCE

Eligible users can now access their personalized 2023 Wrapped experience exclusively in the Spotify mobile app (iOS and Android), and also this year, via web view on mobile or Desktop by heading to Spotify.com/Wrapped. Please make sure your Spotify app is updated to the latest version to access.

New interactive features on 2023 Spotify Wrapped

Here’s what to look out for when you open Spotify. Your Wrapped results can reveal what you were really feeling in 2023.

New data stories bringing you to the heart of their listening: In addition to your top artists, genres, songs, podcasts and minutes listened, we’re adding a few new features to look out for.

○  Me in 2023 celebrates a streaming habit that defined your listening this year. The experience will reveal one of 12 listening characters that best describes the way you listened on Spotify this year – examples include the Shapeshifter (you’re quick to move from one artist to the next), the Luminary (you play light, upbeat music more than others), or the Alchemist (you create your own playlists more than others do).
○  Sound Town matches you to a city based on your listening and shared artist affinity. Listening habits are shared in surprising ways across communities around the world, and 2023 Wrapped celebrates that.

Wrapped fan-favorites appear in a refreshed way users haven’t seen before: 

○  Top 5 Genres story shows you how your top five music genres stacked up with a new sandwich-inspired design.
○  Top 5 Artists lets you see the month your listening peaked for each artist – painting a fuller picture of your entire year and all the moments that made it.
○  You will also get to hear from one of your top artists directly within your personalized Wrapped via Your Artist Messages. You can then visit the Wrapped feed for video messages from thousands of artists including Taylor Swift, MC 張天賦, NewJeans, Jason Chan, Jung Kook and more.

Wrapped Feed: Right on your Spotify Home screen, the Wrapped feed is the one-stop shop for all things Wrapped, including the best of editorial playlists, concerts near you, and more.

Bringing Blend to the Wrapped experience: This year, you can invite your friends to create a Blend and tap the ‘2023 Wrapped Top Songs’ filter to combine all of your top songs from this year into one shared playlist.

– END –

Note to Editors: 

Please find the full top lists of artists, songs, playlists and podcasts in Hong Kong, globally, and in K-Pop HERE.  For more information, visit For The Record. Hi-res images to include in your story are HERE.

ABOUT SPOTIFY

Spotify transformed music listening forever when we launched in 2008. Our mission is to unlock the potential of human creativity by giving a million creative artists the opportunity to live off their art and billions of fans the opportunity to enjoy and be inspired by these creators. Everything we do is driven by our love for music.

Discover, manage, and share over 100 million tracks, including 5 million podcast titles, and 350,000 audiobooks, for free, or upgrade to Spotify Premium to access exclusive features including improved sound quality and an on-demand, offline, and ad-free listening experience.

Today, we are the world’s most popular audio streaming subscription service with a community of more than 574 million users, including 226 million Spotify Premium subscribers, across more than 180 markets. We are also the largest driver of revenue to the music business today.

For more information, images, or to contact the press team, please head over to our press page at https://newsroom.spotify.com/.

Source : 2023 Spotify Wrapped: This Year, Canto-Pop Continues to Top Streams in Hong Kong

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Bespin Global, recognized as ‘MSP Partner of the Year– Global’ winner, one of many AWS Partners around the globe that help customers drive innovation ‘MSP Partner of the Year– Global’, given to the top AWS MSP partner during the year

LAS VEGAS, Nov. 30, 2023 /PRNewswire/ — Bespin Global (https://www.bespinglobal.com/), a company specializing in multi-cloud operations management globally, announced on the 29th that it is a recipient of a 2023 Geo and Global AWS Partner Awards, MSP[1] Partner of the Year – Global.

Bespin Global is recognized with Global MSP Partner of the Year at the ‘2023 GEO and Global AWS Partner Awards’ in Las Vegas. The CEO of Bespin Global, Sunny Kim, and the CEO of Bespin Global Korea, Insoo Chang

As a part of AWS re:Invent 2023, Partner Awards were held in Las Vegas, USA, on the 27th local time. AWS Partner Awards recognize partners whose business models have continued to evolve and thrive over the past year among the wide range of AWS Partners, whose business models have embraced specialization, innovation, and cooperation.

Partner of the Year – Global, awarded by Bespin Global, is given to the best performing MSP among the AWS partners all over the world. As the MSP partner of AWS Bespin Global provides end-to-end AWS solutions to customers at any stage of the cloud journey—from consultation on initial solution design to building applications, through to ongoing optimization and support.

The best practice of Bespin Global is recognized for its achievement in supporting members to make data-based decisions by establishing a new data platform for Korea’s leading electronic company. Through Bespin Global, customers could easily store, classify, and visualize data based on data integration and automated collection. As a result, data analysis and learning can be carried out quickly and efficiently, enabling strategic use of data. By introducing AlertNow, an integrated management platform for cloud incidents[2], the failure rate was reduced by 99% before the adoption.

A Premier consulting partner of AWS, Bespin Global has achieved a variety of AWS Competencies, including Migration, Machine Learning, Data & Analytics, DevOps, and Cloud Management Tools (CMT), demonstrating its capabilities across all areas of the cloud since its foundation in 2015. Based on its expertise and experience in carrying out a large number of data and AI-related projects, it launched an AI MSP service, ‘B2D2’ that supports all areas necessary for the realization of AI business in September.

"We are thrilled to be recognized as the 2023 AWS Global MSP Partner of the Year. This is the result of Bespin Global’s strong capabilities as well as the value and excellence of innovative services provided to customers based on our extensive experience." said Sunny Kim, the CEO at Bespin Global. He added, "Bespin Global committed to innovate continuously for the success of our customers at the forefront of cloud technology based on the close collaboration with AWS."

"It means a lot to us that our customer stories have helped us win this MSP Partner Award," said Insoo Chang, CEO of Bespin Global Korea. "We are receiving a lot of inquiries from Korean companies about using AWS’s AI technology, and we look forward to more achievements in the future."

Meanwhile, the award winners were selected based on strict criteria with a third-party audit conducted by a market research firm, Canalys. The AWS Partner Network (APN) is a global program focused on helping companies build successful AWS-based businesses or solutions by providing business, technical, marketing, and go-to-market support. The APN includes independent software vendors (ISVs) and systems integrators (SIs) around the world, with AWS Partner participation growing significantly during the past 12 months.

[1] MSP: Managed Service Provider

[2] Incident: means any interruption or malfunction that affects the normal operation of a system, network or service.

Source : Bespin Global, Named 2023 AWS Partner Awards 'MSP Partner of the Year- Global'

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

– Dr. Zhiyu Peng, Deputy GM at BGI Genomics, Head of the World Hemoglobinopathy Foundation, and Dr. Androulla Eleftheriou, Executive Director at TIF, analyze findings from the Global 2023 State of Thalassemia Awareness Report

BANGKOK, Nov. 30, 2023 /PRNewswire/ — Thalassemia, a hereditary hemoglobinopathy, occurs in 4.4 out of every 10,000 live births and is prevalent in Mediterranean coastal areas, Africa, the Middle East, Southeast Asia, and southern China.    

Screening and antenatal diagnosis reduced the frequency of β-thalassemia in many Mediterranean countries. Focusing on other regions with high thalassemia prevalence, BGI Genomics has launched the Global 2023 State of Thalassemia Awareness Report, covering 1,847 women from Azerbaijan, China, Indonesia, Kuwait, Saudi Arabia, and Thailand, to assess the level of knowledge and attitudes related to the associated health risks, thalassemia carrier screening, and genetic counseling for carriers.

Dr. Androulla Eleftheriou, Executive Director at Thalassaemia International Federation (TIF), Dr. Zhiyu Peng, Deputy GM at BGI Genomics and Head of the World Hemoglobinopathy Foundation, shared their views on this report’s findings to offer greater insight to improve thalassemia awareness.

Dr. Eleftheriou noted that: "Surprisingly, a substantial number of surveyed individuals displayed a suboptimal understanding of the disease, which could impede effective prevention and control efforts. This report’s findings correspond with TIF’s Global Thalassemia Review 2022, highlighting the necessity to strengthen community awareness about thalassemia and its impact."

As around 70 percent of respondents from these countries with high thalassemia prevalence indicate they do not know much about this disease, Dr. Peng suggested: "There’s room for national thalassemia awareness programs to start earlier and remind people at important milestones. For example, awareness programs could start in middle school and remind both men and women at milestones such as marriage, preparation for pregnancy, and birth." To ensure people know about the ‘why’ and ‘how’ of thalassemia screening, these programs should also cover carrier screening methods such as routine blood tests, hemoglobin electrophoresis, and genetic testing. 

Awareness is crucial for prevention, early detection, targeted therapy, and effective treatment. Dr. Eleftheriou commented that understanding a disease and its symptoms encourages key preventative measures, such as screenings and regular check-ups. Identifying knowledge gaps contributes to tailoring hemoglobinopathy prevention strategies and control initiatives to suit each country’s social, economic, and cultural characteristics.

Which factors will affect your willingness to undergo thalassemia gene screening

This report indicates enhancing awareness, accessibility, and affordability are critical steps in thalassemia control programs. Hospitals or agencies nearby that provide screening services (43.1 percent) and the cost of screening services (38.1 percent) are the top factors affecting the willingness to undergo thalassemia screening.

Dr. Peng shared that in Jiangxi, a Chinese province with a population of around 45 million, genetic testing is recommended for screening thalassemia carriers, further enhancing accessibility and reducing costs. 

The TIF is a non-profit, non-governmental umbrella organization dedicated to improving the lives of patients with thalassemia and hemoglobin disorders globally.

Collaborating with patient organizations, medical professionals, and international, regional, and national health authorities, TIF supports the development of new National Control Programmes and reinforces existing ones for the prevention and management of hemoglobinopathies worldwide.

After noting that TIF has member associations in all the countries covered in this report (Azerbaijan, China, Indonesia, Kuwait, Saudi Arabia, and Thailand), Dr. Eleftheriou shared that: "TIF will continue strengthening its efforts and programs to safeguard patients’ rights and improve their care and benefits."

In 2017, BGI Genomics founded the World Hemoglobinopathy Foundation to fight thalassemia and make the world a better place without this disease. The company has pioneered thalassemia genetic testing services based on next-generation sequencing (NGS) technology since 2013. Dr. Peng reiterated that the company is committed to research to control hemoglobin diseases to cover screening, diagnosis, and treatment.

As part of this mission, the Azerbaijan Thalassemia Center and BGI Genomics sealed a Collaboration Agreement in September 2022 to improve thalassemia screening through genetic technology. To enhance awareness of local medical professionals, the company organized a satellite symposium at the Azerbaijan Laboratory Medicine Congress & Lab Expo in May 2023.

As of the end of June 2023, BGI Genomics has provided thalassemia genetic testing for over 1.4 million people and genetic therapy for six patients, eliminating their dependence on blood transfusion treatment.

Source : Awareness, Accessibility, and Affordability are Crucial for the Early Detection of Thalassemia

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

SHANGHAI, Nov. 30, 2023 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today that its New Drug Application (NDA) for Nefecon® has been accepted for review by South Korean’s Ministry of Food and Drug Safety (MFDS) for the treatment of primary immunoglobulin A nephropathy (IgAN) in adult patients. Nefecon® was the first ever targeted treatment for IgAN approved in the United States, European Union and China. Everest expects to receive NDA approval in South Korea in 2024.

"Everest is committed to expanding Nefecon® regulatory approvals across our licensing territories as IgAN is most prevalent in East Asian population and people of Pacific Asian origin has a significantly increased risk of progressing to end-stage renal disease," said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. "While we look forward to the imminent launch of this first-in-disease therapy in China, where disease prevalence is approximately five million IgAN patients, we also aim to quickly bring Nefecon® to patients throughout Asia including Singapore, Hong Kong, Taiwan and South Korea over the next year to meet urgent needs for innovative therapies like Nefecon® that target disease origin and can delay disease progression."

South Korea’s MFDS granted Global Innovative product on Fast Track (GIFT) designation to Nefecon® earlier this year. Nefecon® was the second product and the first non-oncology product included in MFDS’ GIFT program. Inclusion in the GIFT program is expected to accelerate regulatory review time by 25% and allow for rolling review.

The Phase 3 NefIgArd clinical trial, a randomized, double-blind, multicenter study, evaluated the efficacy and safety of Nefecon® at a once-daily dose of 16 mg, compared to placebo, in adult patients with primary IgAN on optimized RASi therapy. The NefIgArd study is a 2-year trial, which consisted of nine months of treatment with Nefecon® or placebo, followed by a 15-month follow-up period off study drug. The primary endpoint, time-weighted average of eGFR over 2 years, showed a statistically significant and clinically meaningful benefit of Nefecon® over placebo (p-value < 0.0001). It also showed a difference in 2-year total eGFR slope of 2.95 mL/min per 1.73 m2 per year in favor of Nefecon®. The data reflected treatment benefits across the entire study population, regardless of UPCR baseline level.

The full two-year results of the NefIgArd trial (n=364 patients) were further analyzed to assess potential differences in response to Nefecon® treatment based on self-reported Asian (n=83) or White (n=275) ancestry in patients with IgAN. Treatment with Nefecon® 16 mg/day over a 9-month period resulted in clinically meaningful preservation of kidney function in both subgroups, as evidenced by reduction in proteinuria and stabilization of eGFR in these two subgroups when compared to placebo.

About Nefecon®

Nefecon® is a patented oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity that undergoes substantial first pass metabolism. The formulation is designed as a delayed release capsule that is enteric coated so that it remains intact until it releases budesonide to the distal ileum. Each capsule contains coated beads of budesonide that target mucosal B-cells present in the ileum where the disease originates, as per the predominant pathogenesis models.

In June 2019, Everest Medicines entered into an exclusive, royalty-bearing license agreement with Calliditas, which gives Everest Medicines exclusive rights to develop and commercialize Nefecon® in Mainland China, Hong Kong, Macau, Taiwan and Singapore. The agreement was extended in March 2022 to include South Korea as part of Everest Medicine’s territories.

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com. 

Forward-Looking Statements:

This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

Source : Everest Medicines Announces Acceptance of Nefecon® New Drug Applications for the Treatment of Primary IgA Nephropathy in Adult Patients in South Korea

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

MINNEAPOLIS, Nov. 30, 2023 /PRNewswire/ — ShiraTronics, Inc., a pioneering medical device company, today announced the initiation of its groundbreaking RELIEV-CM pilot study in Australia, marking the world’s first seven patients’ successful completion of trial phase procedures for their Chronic Migraine Therapy System. This development underscores the company’s commitment to advancing innovative solutions that provide relief and improved quality of life for the millions of individuals who endure the burdens of chronic migraine disease.

At ShiraTronics, our goal is to help those living with chronic migraine find relief. We’re developing a system designed specifically to target migraine signals within the head and exploring how this may benefit chronic migraine.

Chronic Migraine affects approximately 2% of the global population, inflicting severe headaches, nausea, sensitivity to light, and a severely diminished quality of life, with sufferers experiencing symptoms on at least 15 days each month. For far too many, existing treatments offer little relief. In response to this unmet clinical need, ShiraTronics has engineered a fully implantable system designed to address the symptoms faced by these patients.

Rob Binney, CEO of ShiraTronics, commented, "The initiation of our Pilot Study is a momentous step forward in our mission to alleviate the suffering of those afflicted with chronic migraine. It is our belief that we have developed the world’s first head-located, active implantable designed to address the unmet needs of the millions of patients who are still searching for a solution that can help improve their symptoms and quality of life. We look forward to working with our investigators to demonstrate the safety and efficacy of our novel system, as we prepare for the initiation of our IDE study in 2024."

ShiraTronics Co-Founder and Chairman of the Board, Mudit K. Jain, PhD, remarked, "The first-in-human trial phase study is a critical step in the development of this highly differential novel therapy. I am extremely proud of the efforts of the ShiraTronics team in achieving this major milestone. These efforts will ultimately help us in beating chronic migraine, a devastating disease that impacts millions globally and many people I know personally."  

About the RELIEV-CM Study

The RELIEV-CM Study, conducted in partnership with leading Australian researchers, brings together a team of distinguished neurologists and pain management physicians who will oversee the study’s execution and data collection. The study’s primary objective is to furnish preliminary evidence regarding the performance of the ShiraTronics Chronic Migraine Therapy System, which will inform future clinical research.

The ShiraTronics system delivers precise electrical pulses tailored to disrupt migraine pain signals and aims to offer patients and physicians a new and potentially more effective treatment option.

Dr. Marc Russo, a key contributor to the study, noted, "We have known for very many years the efficacy of nerve stimulation for treating refractory headache syndromes, but the issue has been a lack of custom designed hardware specifically for the cranial region. Here we have access to that for the first time and I think this could open up a vista of treatment options that previously we have shied away from. I’m looking forward to seeing the outcomes from this very important research project."

About ShiraTronics

ShiraTronics, Inc. is a privately held, venture-backed medical device company committed to enhancing the lives of individuals with chronic migraine disease. By harnessing the potential of neuromodulation and pioneering innovative technology, ShiraTronics is at the forefront of the chronic migraine industry, dedicated to enhancing the well-being of chronic migraine sufferers. ShiraTronics achieved FDA breakthrough device designation in 2020 and is headquartered in Minneapolis, MN.

For more information about ShiraTronics and their Chronic Migraine Therapy System, please visit www.shiratronics.com.

Logo – https://mma.prnasia.com/media2/2287881/ShiraTronics.jpg?p=medium600

Source : ShiraTronics Announces Groundbreaking Milestone: World's First Trial Phase Procedures for their Chronic Migraine Therapy System in Australian Pilot Study

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network